New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
04:55 EDTACHC, ACHC, ACHC, BABY, BABY, BABY, CNC, CNC, CNC, INCY, INCY, INCY, AUXL, AUXL, AUXL, HGR, HGR, HGR, ALKS, ALKS, ALKS, ACHN, ACHN, ACHN, MZOR, MZOR, MZOR, LMNX, LMNX, LMNX, IDIX, IDIX, IDIXUBS to hold a conference
Global Healthcare Conference to be held in New York on May 19-21.
News For IDIX;LMNX;MZOR;ACHN;ALKS;HGR;AUXL;INCY;CNC;BABY;ACHC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
09:54 EDTBABYNatus Medical management to meet with Roth Capital
Subscribe for More Information
August 26, 2015
08:33 EDTLMNXLuminex submits 510(k) application for the NxTAG respiratory pathogen panel
Luminex has submitted a 510(k) application to the FDA for the company's NxTAG Respiratory Pathogen Panel, a respiratory assay that will enable laboratories to simultaneously detect 21 respiratory pathogens in a single closed tube system in a format that scales to changes in throughput requirements and responds to seasonal changes in demand.
August 25, 2015
09:26 EDTACHCRBC Capital to hold a bus tour
Healthcare Bus Tour travels throughout Nashville, TN to visit with various healthcare companies on August 25-26.
August 24, 2015
08:11 EDTALKSAlkermes delay for Aristada due to administrative issues, says Jefferies
Jefferies said it appears that the FDA's delay in approving Alkermes' Aristada is due to the agency's need for some additional review time. The firm said the fact that the FDA did not choose to issue a CRL letter gives it confidence that Alkermes should receive full approval in a "few weeks" and it maintains its Buy rating and $76 price target on the stock.
August 23, 2015
12:35 EDTINCYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
16:01 EDTALKSAlkermes provides update on FDA review of ARISTADA
Alkermes announced that the U.S. FDA has advised Alkermes that it will not be able to complete its review of the New Drug Application for ARISTADA for the treatment of schizophrenia by the Prescription Drug User Fee Act action date of Aug. 22, 2015. The FDA indicated that this delay was expected to be brief, measured in terms of weeks, but could not confirm specific timing. The FDA also indicated that no additional data or information is required from Alkermes at this time. "We are confident in the ARISTADA program and our NDA submission, and we will work closely with the FDA as they complete their review," said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. "We look forward to bringing ARISTADA to market as a potential new treatment option to help address the significant unmet medical needs of patients living with schizophrenia."
08:55 EDTINCYIncyte management to meet with JPMorgan
Subscribe for More Information
August 20, 2015
11:49 EDTACHNOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ACHN VIAV ZG RAD DIS ORCL SPY XLF OEX
08:03 EDTCNCCentene subsidiary wins statewide foster care contract
Subscribe for More Information
August 18, 2015
08:41 EDTINCYIncyte shares poised to advance further, says Argus
Argus believes that Incyte's new products make its revenue outlook "promising." The firm thinks the company's "deep" pipeline could enable it to become a takeover target. Argus keeps a Buy rating on the shares.
August 17, 2015
14:11 EDTINCYIncyte reveals favorable early data on IDO inhibitor, says Cowen
Subscribe for More Information
August 14, 2015
17:17 EDTACHNPoint72 gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use